← AbbVie

What podcasts say about AbbVie

Every statement, with the speaker, the exact quote and the moment it was said.

What experts have said about AbbVie

14 statements · 12 positive · 2 negative

  1. Jim LabenthalPositiveNov 11, 2026· Halftime Report

    AbbVie has delivered twice the market return with one-third the market risk.

    “You're getting twice the market return for one-third of the market risk.”

    Listen at 30:46

    Open the episode · AI Relief Rally, Nvidia Governance and CoreWeave Earnings
  2. Jared HolzPositiveOct 22, 2026· CNBC's "Fast Money"

    Investors should wait to buy AbbVie at a lower price.

    “I would just love to buy it cheaper.”

    Listen at 31:28

    Open the episode · Tech Tumbles In Market Sell-Off… And Moderna’s Meltdown After Data Leak 10/22/26
  3. Chef StationPositiveOct 16, 2026· Biotech Bulls & Breakthroughs

    Aldeyra’s potential AbbVie partnership would have approximately 60–40 economics.

    “it would also allow them to go into a partnership where it's pretty much 60-40 AbbVie.”

    Listen at 15:09

    Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is Watching
  4. Jason SnipePositiveOct 16, 2026· Halftime Report

    AbbVie offers a 2.5% dividend and double-digit growth rate

    “We like the 2.5% dividend. We like the double-digit growth rate.”

    Listen at 28:37

    Open the episode · AI debt Fears Fuel Tech Volatility: The Investment Committee's Strategy 10/16/26
  5. Jason SnipePositiveOct 16, 2026· Halftime Report

    The committee initiated AbbVie at 1% and plans to increase it to 5% on weakness

    “we initiated a 1%. position. We ultimately want to get it up to 5% on any pullbacks and any weakness will add to it.”

    Listen at 28:56

    Open the episode · AI debt Fears Fuel Tech Volatility: The Investment Committee's Strategy 10/16/26
  6. Jason SnipePositiveOct 9, 2026· Halftime Report

    AbbVie’s diversification beyond immunology is favorable long term

    “they are expanding outside of the immunology space, which I think is a creative for them long term.”

    Listen at 41:11

    Open the episode · The State of the AI Trade 10/9/26
  7. AbbVie’s technical and growth profile looks favorable.

    “AbbVie looks pretty good.”

    Listen at 15:34

    Open the episode · Stocks Pare Losses As Yields Slash Gains; AbbVie, Apple, Micron In Focus
  8. John FlavinPositiveOct 5, 2026· CNBC's "Fast Money"

    AbbVie’s acquired Cerevel product is currently used for Parkinson’s disease.

    “That product is being used now in Parkinson's.”

    Listen at 29:37

    Open the episode · Strong Dollar Keeps Climbing… And The Outlook For The Pharma Trade 10/5/26
  9. Litowitz made a large bet that the AbbVie-Shire merger would be approved.

    “we had a very large bet that the deal would go through.”

    Listen at 6:05

    Open the episode · E417: $20B Investor on Risk, Uncertainty & Adaptability
  10. The AbbVie-Shire tax-policy uncertainty could not be resolved externally.

    “that uncertainty either couldn't be resolved because it was in the heads of one or two people at Treasury.”

    Listen at 6:49

    Open the episode · E417: $20B Investor on Risk, Uncertainty & Adaptability
  11. Jim CramerPositiveJul 15, 2026· Mad Money w/ Jim Cramer

    Cramer recommends buying AbbVie.

    “I want you to buy it.”

    Listen at 7:50

    Open the episode · Mad Money w/ Jim Cramer 7/15/26
  12. Dan CurtisPositiveJun 22, 2026· Stock Movers

    AbbVie shares are rising nearly 1% premarket.

    “Abbvie shares are actually up about nearly 1% in the pre market.”

    Listen at 2:12

    Open the episode · Arcosa and Apogee Rise; Getty Jumps
  13. Jim CramerNegativeMar 19, 2026· Mad Money w/ Jim Cramer

    AbbVie lost $24 billion in market capitalization after J&J approval

    “AbbVie, here it is, lost $24 billion worth of market capitalization on the approval of the J&J drug.”

    Listen at 22:31

    Open the episode · Mad Money w/ Jim Cramer 3/19/26
  14. Jim CramerPositiveOct 24, 2025· Mad Money w/ Jim Cramer

    AbbVie’s stock will reach $250.

    “I think it goes to 250.”

    Listen at 31:26

    Open the episode · Mad Money w/ Jim Cramer 10/24/25

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.